
FDA Approves Once-Weekly Dosing for Lecanemab-irmb to Treat Early Alzheimer Disease
The anti-amyloid maintenance therapy offers a once-weekly, subcutaneous option after 18 months of intravenous treatment.
The FDA has approved the biologics license application for lecanemab-irmb (Leqembi Iqlik; Eisai), the first and only anti-amyloid therapy to provide a once-weekly, at-home subcutaneous (SC) injection for patients with early Alzheimer disease (AD).1 The weekly autoinjector allows patients and caregivers to continue treatment after completing 18 months of intravenous (IV) infusions.
Lecanemab-irmb will be available in the US starting October 6, 2025.
The FDA’s approval of lecanemab-irmb is supported by data from sub-studies of the phase 3 Clarity AD (
The safety of SC administration was assessed in more than 600 patients across dose ranges, with 49 patients specifically receiving the weekly 360 mg maintenance dose. Importantly, the group had no local or systemic injection-related adverse events. Overall, the safety profile was consistent with IV therapy, though systemic reactions were far less common with subcutaneous dosing.
Approximately 11% of patients experienced mild to moderate local injection-site reactions, while fewer than 1% reported mild systemic symptoms such as headache or fatigue. Amyloid-related imaging abnormalities (ARIA) occurred at similar rates between subcutaneous and IV groups, aligning with background rates in untreated patients. ARIA is most often asymptomatic, though it can be serious or fatal, and typically arises within the first 6 months of IV initiation.
Lecanemab first received FDA accelerated approval in January 2023 for the treatment of AD, making it only the second anti-amyloid therapy cleared for clinical use.2 The decision was based on the phase 2b Study 201 (
In July 2024, the FDA approved a supplemental biologics license application for IV maintenance dosing of lecanemab, offering patients with early-stage AD the option to transition from biweekly to a once-every-4-week dosing after completing 18 months of initiation therapy.3 Recent findings have demonstrated that a monthly maintenance dose preserves the clinical and biomarker benefits of lecanemab, continues to slow disease progression, and helps patients maintain cognitive and functional abilities.
The SC maintenance option with lecanemab-irmb offers meaningful advantages for both patients and the health care system, according to a press release by Biogen.1 For patients and care partners, the ability to self-administer treatment at home reduces the burden of frequent visits to infusion centers, shortens treatment time, and supports long-term adherence.
“Health care providers reported that the device has the potential to provide a new option for patients who are responding well to Leqembi and should continue treatment,”
References
1. FDA approves Leqembi Iqlik (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer's disease. News release. Biogen. August 29, 2025. Accessed September 2, 2025.
2. Joszt L. FDA approves lecanemab to treat early Alzheimer disease. AJMC®. January 6, 2023. Accessed September 2, 2025.
3. McCormick B. FDA approves new maintenance dosing for lecanemab to treat early-stage Alzheimer disease. AJMC. January 27, 2025. Accessed September 2, 2025.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.